Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013:2013:589451.
doi: 10.1155/2013/589451. Epub 2013 Jun 12.

The effect of diabetes-associated autoantigens on cell processes in human PBMCs and their relevance to autoimmune diabetes development

Affiliations

The effect of diabetes-associated autoantigens on cell processes in human PBMCs and their relevance to autoimmune diabetes development

Jana Vcelakova et al. J Diabetes Res. 2013.

Abstract

Type 1 Diabetes (T1D) is considered to be a T-helper- (Th-) 1 autoimmune disease; however, T1D pathogenesis likely involves many factors, and sufficient tools for autoreactive T cell detection for the study of this disease are currently lacking. In this study, using gene expression microarrays, we analysed the effect of diabetes-associated autoantigens on peripheral blood mononuclear cells (PBMCs) with the purpose of identifying (pre)diabetes-associated cell processes. Twelve patients with recent onset T1D, 18 first-degree relatives of the TD1 patients (DRL; 9/18 autoantibody positive), and 13 healthy controls (DV) were tested. PBMCs from these individuals were stimulated with a cocktail of diabetes-associated autoantigens (proinsulin, IA-2, and GAD65-derived peptides). After 72 hours, gene expression was evaluated by high-density gene microarray. The greatest number of functional differences was observed between relatives and controls (69 pathways), from which 15% of the pathways belonged to "immune response-related" processes. In the T1D versus controls comparison, more pathways (24%) were classified as "immune response-related." Important pathways that were identified using data from the T1D versus controls comparison were pathways involving antigen presentation by MHCII, the activation of Th17 and Th22 responses, and cytoskeleton rearrangement-related processes. Genes involved in Th17 and TGF-beta cascades may represent novel, promising (pre)diabetes biomarkers.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Verification of gene microarray data. Relative expression of TGF beta1, STAT3, and CD4 by qRT-PCR (data were obtained from an independent cohort of 14 newly diagnosed patients with T1D and 12 healthy volunteers).
Figure 2
Figure 2
Genes differentially activated in each group (cluster formation). The enhanced gene expression heatmap was constructed using probe signal intensities that had a log fold change that was greater than +1 or less than −1. Genes that were significantly altered in the relatives group clustered into specific gene families.
Figure 3
Figure 3
Immune response and Th17 cell differentiation. Differences in Th17 polarisation were observed when controls were compared with T1D patients using microarray data. Genes of interest were analysed by qRT-PCR and were found to be upregulated in T1D patients. STAT3 and TGF-beta were chosen as representatives of Th17 cell differentiation. Microarray data demonstrated that CD4 was one of the most significantly upregulated molecules in T1D patients.

References

    1. Castano L, Eisenbarth GS. Type-I diabetes: a chronic autoimmune disease of human, mouse, and rat. Annual Review of Immunology. 1990;8:647–679. - PubMed
    1. Foulis AK, Farquharson MA, Meager A. Immunoreactive α-interferon in insulin-secreting β cells in type 1 diabetes mellitus. The Lancet. 1987;2(8573):1423–1427. - PubMed
    1. Atkinson MA, Kaufman DL, Campbell L, et al. Response of peripheral-blood mononuclear cells to glutamate decarboxylase in insulin-dependent diabetes. The Lancet. 1992;339(8791):458–459. - PubMed
    1. Staeva-Vieira T, Peakman M, von Herrath M. Translational mini-review series on type 1 diabetes: immune-based therapeutic approaches for type 1 diabetes. Clinical and Experimental Immunology. 2007;148(1):17–31. - PMC - PubMed
    1. Ludvigsson J, Faresjö M, Hjorth M, et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. New England Journal of Medicine. 2008;359(18):1909–1920. - PubMed

MeSH terms

LinkOut - more resources